DOSAGE INDEX / SINGLE
Testagen
Research, reported schedules and supply planning.
Understand Testagen cell localization, DNA-interaction research and a separate corrosion study, with clear limits on testosterone and fertility claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–300 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 20 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Testagen is identified as Lys-Glu-Asp-Gly, abbreviated KEDG, in an original cell-localization and DNA-interaction study. Researchers examined fluorescently labeled material in HeLa cells and tested interactions with nucleic-acid structures. Those experiments do not demonstrate increased testosterone, improved fertility or an endocrine reset. [1]
- The 2011 study reported fluorescence in the cytoplasm, nucleus and nucleolus after cells were incubated with labeled peptides, including Testagen. Separate assays with intact peptides found sequence-dependent fluorescence changes in DNA-related complexes. The authors proposed preferential interactions with particular nucleotide sequences. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 10 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original 2011 study
- MDPI MoleculesFurther reading · Listed in reference bibliography.
- MDPI MoleculesFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- MedlinePlusGeneral guidance · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.